Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)
Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%
Castle Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Castle Biosciences's ebitda for the twelve months ending Sep 30, 2026 was -$12.08M, down 254.3% year over year. For fiscal 2025 it was -$2.04M, down 108.3% from the year before. The highest annual figure on record is $24.67M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.04M | -108.3% |
| FY2024 | Dec 31, 2024 | $24.67M | – |
| FY2023 | Dec 31, 2023 | -$55.65M | – |
| FY2022 | Dec 31, 2022 | -$62.31M | – |
| FY2021 | Dec 31, 2021 | -$36.67M | – |
| FY2020 | Dec 31, 2020 | -$6.07M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.45M | – |
| Q2 FY2026 | Jun 30, 2026 | $1.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.48M | -888.6% |
| Q4 FY2025 | Dec 31, 2025 | -$50.00K | -100.5% |
| Q3 FY2025 | Sep 30, 2025 | -$2.99M | -134.7% |
| Q2 FY2025 | Jun 30, 2025 | -$837.00K | -110.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.84M | – |
| Q4 FY2024 | Dec 31, 2024 | $9.82M | – |
| Q3 FY2024 | Sep 30, 2024 | $8.62M | – |
| Q2 FY2024 | Jun 30, 2024 | $8.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.13M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.43M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.47M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.63M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.99M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.73M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.18M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.05M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.87M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.78M | – |
See a number that looks wrong?